Skip to content

Quick ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.1×0.0×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
6.1×+1.2×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Beam Therapeutics logo
Beam TherapeuticsBEAM
17×+8.2×
Regenxbio logo
RegenxbioRGNX
2.6×-0.3×

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Calculated from Prime Medicine’s reported figures.

Based on the most recent quarter.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's quick ratio?
Prime Medicine (PRME) reported quick ratio of 3.8× in Q1 2026.
How has Prime Medicine's quick ratio changed year-over-year?
Prime Medicine's quick ratio decreased by 20.4% year-over-year, from 4.8× to 3.8×.
What is the long-term trend for Prime Medicine's quick ratio?
Over 4 years (2021 to 2025), Prime Medicine's quick ratio has grown at a 0.9% compound annual growth rate (CAGR), from 4.7× to 4.8×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.